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The global burden of alveolar echinococcosis
Abstract
BACKGROUND: Human alveolar echinococcosis (AE) is known to be common in certain rural
communities in China whilst it is generally rare and sporadic elsewhere. The objective of this study was
to provide a first estimate of the global incidence of this disease by country. The second objective was to
estimate the global disease burden using age and gender stratified incidences and estimated life
expectancy with the disease from previous results of survival analysis. Disability weights were
suggested from previous burden studies on echinococcosis.
METHODOLOGY/PRINCIPAL FINDINGS: We undertook a detailed review of published literature
and data from other sources. We were unable to make a standardised systematic review as the quality of
the data was highly variable from different countries and hence if we had used uniform inclusion criteria
many endemic areas lacking data would not have been included. Therefore we used evidence based
stochastic techniques to model uncertainty and other modelling and estimating techniques, particularly
in regions where data quality was poor. We were able to make an estimate of the annual global
incidence of disease and annual disease burden using standard techniques for calculation of DALYs.
Our studies suggest that there are approximately 18,235 (CIs 11,900-28,200) new cases of AE per
annum globally with 16,629 (91%) occurring in China and 1,606 outside China. Most of these cases are
in regions where there is little treatment available and therefore will be fatal cases. Based on using
disability weights for hepatic carcinoma and estimated age and gender specific incidence we were able
to calculate that AE results in a median of 666,434 DALYs per annum (CIs 331,000-1.3 million).
CONCLUSIONS/SIGNIFICANCE: The global burden of AE is comparable to several diseases in the
neglected tropical disease cluster and is likely to be one of the most important diseases in certain
communities in rural China on the Tibetan plateau.
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Introduction
Human alveolar echinococcosis (AE) is caused by the larval
stage of the fox tapeworm Echinococcus multilocularis. It is amongst
the world’s most dangerous zoonoses. Transmission of AE to
humans is by consumption of parasite eggs which are excreted in
the faeces of the definitive hosts: foxes and, increasingly, dogs.
Naturally the parasite transmits between foxes or dogs and small
mammals whilst humans are aberrant intermediate hosts
(Figure 1). Human infection can be through direct contact with
the definitive host or indirectly through contamination of food or
possibly water with parasite eggs. Geographically E. multilocularis is
confined to the northern hemisphere, but within that range has a
wide distribution (Figure 2) [1]. In humans, infection results in a
metacestode in the liver. This is a slowly growing infiltrative space
occupying lesion. If untreated, this lesion will result in clinical signs
such as abdominal mass and/or pain, jaundice, and ultimately
liver failure [2]. In the late stages of the disease, the parasitic lesion
can metastasize resulting in a variety of symptoms. Treatment
options include liver resection to remove the parasite mass and
chemotherapy using benzimadazoles is now being increasingly
used. Survival analysis indicates that with judicious surgical and
chemotherapeutic treatment the prognosis is relatively good [3].
However, chemotherapy is required continuously for many years,
sometimes for the remainder of the patient’s life to achieve success.
In the absence of this expensive treatment the disease normally has
a fatal course.
Human AE is an emerging disease in Europe. Studies in wildlife
are detecting the parasite in new areas [4]. It is not yet clear if the
parasite range is spreading or increasing surveillance has lead to
greater detection rates. What is certain is that increasing fox
populations in Europe are correlated with the greater numbers of
cases of AE reported in Switzerland [5]. In Asia a major endemic
focus was detected in China [6] with large numbers of human
cases – in some communities 5% or more of the population is
infected [7]. In such areas there is, not only high infection rates in
humans, but a high prevalence of infection with the adult parasite
in the dog population [8]. In central Asia there are also reports of a
spill over of E. multilocularis into the dog population [9] and this
may indicate an increasing threat of transmission to humans.
Elsewhere there are increasing reports of AE being detected by
surgeons in countries such as Russia and Turkey.
Control of the parasite is possible, for example, through the
judicious use of praziquantel baits distributed to foxes [10]. Some
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studies have indicated that risk factors such as contamination of
food or water are a likely conduit of human infection [11,12] and
could suggest alternative strategies to prevent human infection.
However, whatever the intervention strategy, the economic
efficiency of control will depend upon the societal burden of
disease. The purpose of this study was to estimate the annual
global burden of AE.
Materials and Methods
Initially all countries, endemic for E. multilocularis, were
identified. These were countries that were known to have
autochthonous human cases of AE and/or E. multilocularis
identified in animal populations. In addition, neighbouring
countries where there were no known reports were also identified
as likely endemic areas. The list of countries believed to be
endemic for E. multilocularis is given in Table 1.
Sources of information
Literature searches were undertaken in any relevant databases
that could be accessed. These included all the following scientific
databases: Pubmed, Medline, Science Citation Index, Scopus,
East View (Chinese and Russian databases), Russian Scientific
electronic library, and Google Scholar. This was supplemented by
direct contacts with known persons working in the field in various
countries. In addition, further information was solicited by directly
contacting individuals who had authored manuscripts by the email
address in the correspondence section. Key words used were
Echinococcus multilocularis and alveolar echinococcosis for initial
screening. Where appropriate the search term was also translated
into the language of the relevant database. For each country a
systematic search was undertaken to locate data from that country
eg Echinococcus multilocularis AND France. All literature was initially
screened. Most literature was not useful for calculating incidence
rates (for example individual surgical case reports); although in a
number of cases such individual reports confirmed that the disease
was endemic in the country or region of interest. Inclusion criteria
depended on the amount of available information from that
country. Because of wide variability in the quality of the data from
different countries it was not possible to use a standard procedure
across all endemic countries. When there were extensive
prevalence and/or incidence reports, particularly indicating whole
country incidences, these were used as the primary data sources.
However, for many if not most countries, such data was not
available. In these cases the reports of individual cases or case
studies were utilized to, at the very least, prove the presence of the
disease (and in a few cases there were only reports from animal
infections). The body of literature on experimental research (eg
experimental infections of definitive or intermediate hosts) was, in
the whole, of little relevance to this study.
Calculations of incidence
For a number of countries such as Switzerland [5] or Germany
[13], accurate figures for the annual numbers of cases were easily
identified. This is because they had up to date national databases
and/or accurate methodology for capturing the estimated
numbers of cases each year. In other countries, such as
Kyrgyzstan, accurate reporting figures were available based on
histological confirmed cases presented for treatment from hospitals
(unpublished). However, it is believed that, in low-income
countries such as Kyrgyzstan, the reported cases are likely to
substantially underestimate the total numbers of cases as a
substantive number of cases are likely to remain undiagnosed
because of the relative expense of seeking medical treatment.
China is believed to account for the majority of global AE cases.
Estimates were based on mass screenings by ultrasound giving a
prevalence estimate. Many such reports also indicated groups
(such as Tibetan pastoralists) who were at particular risk of
infection. In this region there were a number of large prevalence
studies and epidemiological studies based on ultrasound confir-
mation of diagnosis. These often consisted of several thousand
individuals and hence gave samples of populations at risk. In
addition particular groups at risk such as Tibetan pastoralists were
identified. The studies used are given in Table 2. In total in studies
spanning the first decade of the 21st century over 36,000
individuals have been screen by ultrasound over large areas of
Ningxia autonomous region, Sichuan, Gansu, and Qinghai
provinces. The total number of individuals currently affected with
AE was estimated from these prevalence studies and the total
populations at risk. This data was then converted into an annual
incidence of AE for these populations. Survival analysis of a series
of cases from Switzerland suggested that the 50% survival rate of
approximately 8 years if treatment is not available for individuals
with a mean age of presentation in their early 50s [3]. This can rise
to approximately 11 years for younger subjects. If endemic
stability is assumed then there will be approximately 6.1% of
infected young adults dying from the disease rising to approxi-
mately 8.2% of infected adults who are aged in their early 50s.
Hence the annual incidence is approximate 6.1%–8.2% of the
detected ultrasound prevalence in the population of these
respected age groups.
China has large populations in rural areas that are potentially
exposed to this parasite. An estimate was performed of the
population at risk by examining population data county by county
from Chinese Census data. The estimates of the mean prevalence
in the population at risk were estimated from relative risk of
various ethnic communities from population studies and the
proportions these communities make up in the general population.
There are also reports of AE in inner Mongolia and Xinjiang but
these tend to have considerably few cases then the main endmic
area of the Tibetan plateau.This prevalence data was extrapolated
Author Summary
Human alveolar echinococcosis (AE), caused by the larval
stage of the fox tapeworm Echinococcus multilocularis, is
amongst the world’s most dangerous zoonoses. Transmis-
sion to humans is by consumption of parasite eggs which
are excreted in the faeces of the definitive hosts: foxes and,
increasingly, dogs. Transmission can be through contact
with the definitive host or indirectly through contamina-
tion of food or possibly water with parasite eggs. We made
an intensive search of English, Russian, Chinese and other
language databases. We targeted data which could give
country specific incidence or prevalence of disease and
searched for data from every country we believed to be
endemic for AE. We also used data from other sources
(often unpublished). From this information we were able
to make an estimate of the annual global incidence of
disease and disease burden using standard techniques for
calculation of DALYs. Our studies suggest that AE results in
a median of 18,235 cases globally with a burden of 666,433
DALYs per annum. This is the first estimate of the global
burden of AE both in terms of global incidence and DALYs
and demonstrates the burden of AE is comparable to
several diseases in the neglected tropical disease cluster.
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to the estimated population at risk and then converted to incidence
based on the results of survival analysis [3].
A flow chart illustrating the methodology used in the study is
given in figure 3.
Incidence estimates from case series
In Turkey and Russia total numbers of cases for echinococcosis
are recorded. In Russia in 2002 there were 3,274 cases of cystic
echinococcosis (CE) notified [14]. In Turkey 14,789 cases of CE
were notified in the 5 years 2001–2005 [15]. Separate information
for AE was not available. This may be because it has only recently
been made notifiable such as in Turkey [16] or because CE and
AE cases are not distinguished in official figures. Despite this, in
Turkey there are some nationwide figures which give a minimum
estimate. However, there are a number of case series of
echinococcosis published by surgical units which differentiate
between CE and AE. The relative proportion of AE to CE cases in
such surveys can be used to estimate the likely number of AE cases
for the whole country. These case series (Tables 3 and 4) are a
means to calculate the total incidence of AE from the relative
incidence and total country incidence of CE. In addition, in
Turkey there was one detailed case series of echinococcosis with
CNS involvement that identified 16 cases of AE with cerebral
involvement over a 5 year period from neurosurgical units in
Turkey [17]. A large study in China suggested that 4% of AE cases
had neurological involvement [18]. Likewise, a large European
study found 17 of 559 (3%) cases of AE had brain involvement
[19]. The likely number of AE cases can then be estimated by
assuming that the proportion of cerebral AE cases in Turkey was
similar to these reported case series.
Estimates of DALYs
To calculate DALYs standard techniques were used [20]. The
years of life lost (YLLs) were calculated on the assumption that the
disease is fatal within an average of 8 years of diagnosis if
untreated. If treatment is available then the prognosis was assumed
to be reasonable with just 2–3 YLLs. These assumptions are based
on previously published survival analysis [3]. In order to calculate
the years lived with disability (YLDs) is was necessary to assign a
disability weight. As no accepted disability weight has yet been
assigned to alveolar echinococcosis the disability weight for
carcinoma of the liver was used as previously [7]. The years lived
with the disability again depends on where the cases are presented
and available treatment options. Where there is no treatment,
Figure 1. The life cycle of Echinococcus multilocularis. Man is infected as an aberrant intermediate host.
doi:10.1371/journal.pntd.0000722.g001
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death can be assumed within a mean of 8 years for patients in their
50s, but this increases to 11 years for someone presenting in their
20s [3]. In low income countries a disability weight for pre
terminal liver cancer (0.200) was assigned for 6–9 years with a
disability weight for 2 years living at the disability weight for
metastatic and terminal stages (0.75–0.81) [21] .The number of
years at these weights depended on the age specific incidence (see
below). In those countries where advanced medical treatments
lead to a successful outcome, a disability weight of 0.200 for mild
disease for the average length of treatment (7 years) [3]. This was
based on the fact that liver cancer has similar symptomatology to
AE [7].
Age and gender specific incidence
This data are important in estimating the burden of disease. For
Europe a large data set of 559 [19] was used as the basis for the
age and gender distribution of cases and hence the age weighting
and YLLs for the estimated DALYs. For China prevalence data
only was available, but much was age and gender stratified and
was used to calculate the age and gender specific incidence after
adjusting for bias by comparing the sampled population with the
age and gender profile of the general population using census data
[7]. Other counties including Turkey had case series reports which
indicated age and gender of cases, although in some instances only
the mean age was given. Unpublished data for case series from
Kyrgyzstan were used and assumed to be representative of similar
ex-Soviet states where data was not available.
Stochastic analysis
Based on the quality of the data we were able to assume some
countries (eg Switzerland) had accurate estimates of incidence,
whilst others it was much more uncertain, particularly when
estimates had to be created from modelling or extrapolation from
neighbouring regions. A Monte-Carlo routine was written to
resample estimates of incidence from each country based on the
likely probability distribution of the total case incidence. This was
similar to methods described previously [7,22]. Distributions were
based on a number of factors from the available data including
possibilities of missing data.
Results
Incidence
For China in total we estimated there are 230,000 individuals
presently suffering from AE and a total population at risk of some
22.6 million in 7 provinces (Table 5). Assuming most of these go
untreated and hence have a fatal outcome, this was used to
estimate the incidence from age stratified life expectancy following
diagnosis. This gives an annual incidence of approximately 16,629
new cases per annum.
Russia is a huge endemic area stretching from Eastern Europe
to Siberia. We estimated that there are approximately 1,180 cases
per year in this country. AE is found throughout the northern
parts of Asia with important foci in central Asia and Turkey. The
estimates for the annual numbers of cases in Asia excluding Russia
are given in Table 6. The estimated numbers of cases from Europe
from countries that are endemic for AE are given in the Tables 7
and 8, with the references supporting the estimate. Although
North America is endemic for E. multilocularis in animal hosts there
is very little evidence for transmission to humans presently.
We estimate that the median estimate of the total numbers of
AE cases in the world is 18,235cases per year with 95% CIs of
11,932–28,156. Of these 91% of cases are believed to be in China
with just 1,606 occurring outside China.
Figure 2. Global distribution of AE.
doi:10.1371/journal.pntd.0000722.g002
Burden of Alveolar Echinococcosis
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Estimated DALYs
Globally YLLs due to AE was estimated at 616,897 (CIs
296,485 – 1.2 million). Again China had most of YLLs and as a
proportion was even higher than the incidence as it was assumed
that the majority of cases in China did not receive treatment. The
age of onset was also younger then compared to Europe. Thus,
whilst China had 91% of the global number of cases it is believed
that it has 95% of the YLLs due to alveolar echinococcosis. The
total number of DALYs per annum for the world is estimated at a
median of 666,433 (CIs 331,539 – 1.3 million).
Discussion
This report represents a first attempt to estimate the global
burden of AE although the global geographical distribution of E.
multilocularis has been reviewed previously (e.g. [2]). Throughout
much of its geographical range AE is sporadic in humans. In high
income countries such as Germany and Switzerland the numbers
of cases were the actual number reported (Switzerland) [5].
Alternatively in Germanyreported figures were based on a
reported capture recapture technique which modelled underre-
porting [13]. These are believed to be accurate reports of the
numbers of cases. Reviews of published data also gave estimates
for a number of other upper income countries.
For some lower income studies there was limited official data
(unpublished) reporting the total number of cases presenting for
treatment. However in such countries a major underestimation of
the numbers of cases is possible as only relatively wealthy
individuals can pay for medical care and the majority of cases
may not present for treatment and hence go undiagnosed. A
criticism of our approach is that we did not use consistent inclusion
criteria for data in different countries. What we did use was the
best available data and balanced this inconsistency by using a
stochastic approach to model uncertainty. In the countries where
we believed the data was accurate a very narrow probability
distribution was chosen for the Monte-Carlo routine. In contrast
where there was poor data, a very wide distribution was used to
model this uncertainty. Hence, the median incidence and
estimated DALYs together with the 95% confidence limits give
a good estimate of the burden of AE.
In certain districts of China several studies have indicated a very
high prevalence of AE through mass screening studies. Surveys
have consistently shown a high prevalence of AE using ultrasound
studies across Sichuan, Gansu, Qinghai, and Ninxia (Table 2).
This confirms that there are large numbers of AE cases in China
and these represent at least 91% of the global incidence. In some
communities the prevalence of AE is similar to that of tuberculosis
[23]. Because of the large population at risk and the consistent
finding of high prevalences we believe the estimate of the number
of cases in China is representative. However, the prevalence is not
uniform with variations within these districts of between ,1% to
12%. The calculations have tried to accommodate these variations
in arriving at an overall incidence figure. In the Tibet Autonomous
Region (TAR), the incidence could be much higher than the
Table 1. Countries believed to be endemic for E.
multilocularis over at least part of their territory.
Europe Asia North America
Austria Afghanistan Canada
Belgium Armenia USA
Belorussia Azerbaijan
Bulgaria Bhutan
Croatia China
Czech Republic Georgia
Denmark India
Estonia Iran
France Iraq
FYR Macedonia Japan
Germany Kazakhstan
Greece Kyrgyzstan
Hungary Nepal
Italy Mongolia
Kosovo Pakistan
Latvia Russia*
Liechtenstein Tajikistan
Lithuania Turkey
Luxembourg Turkmenistan
Moldova Uzbekistan
Montenegro
Netherlands
Poland
Rumania
Russia*
Serbia
Slovakia
Slovenia
Switzerland
Ukraine
*Both European and Asian parts of Russia include large endemic areas.
doi:10.1371/journal.pntd.0000722.t001
Table 2. Population studies for AE in rural China.
Region
Number
with AE
Population
size studied Reference
Ningxia (Xija, Guyuan and Haiyuan
counties
96 4778 [51]
Sichuan (Ganzu autonomous
prefecture)
308 8512 [52]
Gansu (Dingxi prefecture) 114 3836 [53]
Qinghai 39 1549 [54]
Sichuan 60 705 [55]
Gansu 84 2482 [56]
Gansu (Ming and Zhang counties) 86 2485 [57]
Qinghai (Zhiduo County) 2 979 [58]
Qinghai (Chindu, Zeko and Gade
counties)
31 3703 [59]
Sichuan (Ganzi and Shiqu counties) 223 7138 [12]
Ningxia Hui Autonomous
Region (Xiji County)
20 221 [60]
*Total 1063 36388 2.9%
+Gansu (Zhang county) 65 1312 [6]
*Total of studies in the last 10 years.
+Study from 1992.
doi:10.1371/journal.pntd.0000722.t002
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figures suggested. Tibetan communities in neighbouring districts
of Sichuan for example have very high prevalences. The parasite is
known to be endemic in TAR, but there is no published human
surveillance data. We were only able to assume that prevalences in
the eastern most part of TAR were similar to prevalences in
neighbouring counties of Sichuan or Qinghai. It is possible,
therefore, that the true incidence could be thousands rather than
the hundreds that are suggested. There is a single case report of
cerebral AE in a Tibetan monk who originated from Lhasa which
is quite some distance west of the known highly endemic areas of
Gansu, Qinghai, and Sichaun [24] which is evidence that the
parasite has a greater range than our conservative assumption. In
Xingjiang the parasite is endemic, but human studies have mainly
uncovered cases along the northwest of the province and hence the
population at risk and actual case numbers are calculated
accordingly.
Table 3. The relative numbers of CE:AE cases in various
studies from Turkey.
Number of CE Number of AE Reference
44 6 [61]
72 8 [62]
196 47 [63]
109 39 [64]
203 16 [17]*
336 11 [17]**
138 20 [65]
111 22 [66]
*Intracranial echinococcosis only. Case searching from 47 neurosurgical units
between 1994 and 1999.
**Intracranial echinococcosis only. Reported literature cases from Turkey from
1940s–1990s.
doi:10.1371/journal.pntd.0000722.t003
Table 4. Published case report series from Russia.
Number of CE Number of AE Reference
48 24 [67]
95 40 [68]
44 84 [27]*
*These data are from districts of Siberia where AE relative incidence might be
expected to be higher.
doi:10.1371/journal.pntd.0000722.t004
Figure 3. Flow chart illustrating the search methods and processing of information.
doi:10.1371/journal.pntd.0000722.g003
Burden of Alveolar Echinococcosis
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Russia is a large endemic area for alveolar echinococcosis. In
some districts, particularly in Siberia there are reports of a number
of human cases whilst elsewhere the disease is sporadic. Detailed
data is somewhat lacking despite intensive search of English and
Russian language databases. Most data is reported in terms of
hospital reports and is therefore estimated as an annual incidence.
There are no mass ultrasound surveillance studies as in China
although there are a few mass serological studies which tend to
confirm the potential for large numbers of cases, especially in
Siberia. It is clear, however, that the disease occurs sporadically
across almost the entire country. Even in districts where there are
no reported human cases there are reports of the parasite in
animal hosts so transmission to humans is likely. The estimates for
the whole of Russia initially relied on extrapolating data from
districts where there were known reports or unpublished data.
Bassonov wrote an extensive monograph [25] detailing the
epidemiology of echinococcosis throughout countries of the former
Soviet Union including summaries of otherwise difficult to obtain
material. This was also used as a basis for estimating the numbers
of cases in Russia. In addition, we were able to access some local
Russian language reports including articles in local newspapers
and these largely confirmed our assumptions [26]. Estimates based
on the samples from case series (essentially a type of capture
recapture technique) described in the text tended to confirm these
estimates. We assumed a maximum ratio of 1:2 for AE:CE.
However, one study of surgical cases from Omsk in western
Siberia described 84 cases of AE and 44 cases of CE [27]. As most
of these cases were from Siberian districts such as Kemerova,
Altai, Yakutia and Tomsk which could indicate higher numbers of
AE than the ratios we used in our calculations.
Table 5. Estimated annual numbers of new cases in endemic
provinces of China.
Chinese
province
Population
at risk
Estimated
prevalence
Estimated median
number of new
cases per year
Gansu 3.6 million 2.9% 7676
Inner Mongolia 3 million 0.02% 44
Qinghai 5.4 million 1.0% 3766
Ningxia 1.2 million 2.0% 1770
Sichuan 0.92 million 3.6% 2390
Tibet Autono-
mous Region
2.7 million 0.1% 172
Xinjiang 5.8 million 0.2% 811
doi:10.1371/journal.pntd.0000722.t005
Table 6. Estimated annual incidence of AE in Asia, by
country.
Country
Estimated
Number of Cases
Afghanistan 1 Single case report [31]
Armenia 3 Estimated
Azerbaijan 6 Estimated
Bhutan ,1 No data
China 16,629 See table 5
Georgia 6 Estimated
India 1 Two case reports [29,30]
Iran 11 Estimated
Iraq 1 Single case report [33]
Japan 12 Reported cases [69]
Kazakhstan 39 Estimated
Kyrgyztan 17 Actual figures (unpublished)
Mongolia 9 Actual figures (unpublished)
Nepal ,1 No data
Pakistan ,1 No data
Russia* 1180 See text
Tajikistan 20 Estimated
Turkmenistan 2 Estimated
Turkey 100 Estimated and modelled from
various data (see text)
Uzbekistan 24 Estimated
*Including European Russia.
doi:10.1371/journal.pntd.0000722.t006
Table 7. Estimated median annual numbers of cases from
Eastern Europe.
Country
Estimated annual
number of cases Source
Belorussia 6 Border districts of Lithuania have
cases
Bulgaria 1 Estimated
Czech republic 1 Estimated
Estonia 9 Similar to Lithuania
Greece 1 1 case reported from 1980 to 2000
[70]
Hungary 1 First case reported 2004 [71]
Latvia 9 Similar to Lithuania
Lithuania 9 Reported cases [40]
Macedonia 1 One case reported in 10 years [72]
Moldova 1 Estimated
Poland 3 1992–2007, 45 cases recorded [73]
Slovakia 4 Four cases in 2007 [74]
Slovenia 2 0.45 per 100,000 over 5 years [75]
Ukraine 10 Estimated. Endemic [25]
doi:10.1371/journal.pntd.0000722.t007
Table 8. Estimated annual numbers of cases of AE in Central
and Western Europe.
Country
Estimated annual
number of cases Reference
Austria 7 [19,76]
Belgium 1 [19,77]
France 21 [68]
Germany 61 [78]
Switzerland 20 [3,5]
doi:10.1371/journal.pntd.0000722.t008
Burden of Alveolar Echinococcosis
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The mountainous regions of Kazakhstan, Kyrgystan, Uzbeki-
stan, and Tadjikistan are all endemic for E. multilocularis [28]. Here
the cycle of infection has been well described in terms of the
animal hosts. The most accurate figures available are from
Kyrgyzstan where approximately 35 cases per years are now being
reported in the hospitals (unpublished figures from the Govern-
ment Epidemiological Surveillance Unit, Bishkek). This figure is
likely to be accurate in terms of numbers being treated. However,
it may underestimate the actual numbers of cases occurring as the
country is poor and expensive medical treatment is not available to
a large part of the population.
Although ethnically distinct, in terms of geography and
economy, Tadjikistan is very similar to Kyrgyzstan. Therefore,
as it is also endemic for E. multilocularis, similar numbers of cases
per year could be expected as there is likely a similar population
size at risk. Kazakhstan and Uzebkistan are much larger countries
in area and population but as much of their territory is in low or
non-endemic areas the proportion of population at risk is smaller,
but absolute numbers are similar. Turkmenistan is likely to have
few cases of AE, as much of the territory is arid desert which is
inimical to transmission. Mongolia has a number of reported
cases. From unpublished data there were 9 cases of AE in both
2006 and 2007.
India, Nepal, Bhutan and Pakistan border on endemic zones
and may have a few cases. The disease has been reported in India
(Kashmir) [29,30]. For Afghanistan, data is not available.
However there is a case report of a patient originating from
Afghanistan who was treated in the UK (which is non endemic)
[31]. Therefore, further cases are likely, especially in the north of
the country. Iran is endemic for AE but there is little data.
Between 1948 and 1993, 37 cases of AE were reported [32] or less
than 1 case per year. In view of the fact that neighbouring Turkey
is known to be highly endemic this is likely underreported. There is
a single case report of AE from northern Iraq [33].
Turkey is highly endemic for echinococcosis. In total,
approximately 3000 cases are recorded annually. The number of
cases of AE is uncertain. The proportion of cases of echinococcosis
that are AE have been reported in a number of case series
(Table 3). Assuming a similar ratio of AE to CE nationwide as
found in the case report series this would suggest as many as 500
cases of AE per year. However, such selected case series may
overestimate the true incidence of AE and these data contrast
somewhat with the report of 206 cases of AE in Turkey for the
period 1980–2000 or just 10 cases per year [34]. AE has only
recently been made reportable in Turkey [16] and so more
accurate figures are unavailable. Also of interest is a case finding
study which specifically searched through the records of 47
neurosurgical units for cases of cerebral echinococcosis. This study
found a total of 219 cases of intracranial echinococcosis in the five
year period 1994–1999 [17]. Of these 16 were AE and 2 were AE
with no extra CNS involvement. Another report found 4 CNS
cases of AE in just 27 months at one centre [35]. Intracranial AE is
thought to be rare with CNS involvement usually a manifestation
of metastases from a primary lesion. A large study in China
suggested that 4% of AE cases had neurological involvement [18].
Likewise, a large European study found 17 of 559 (3%) cases of AE
had brain involvement [19]. The incidence of diagnosed
intracranial cases of AE therefore gives strong evidence there
must be at least 100 cases of AE per year in Turkey. This type of
approach may, nevertheless, substantially underestimate AE cases
in resource poor endemic regions, as a smaller proportion of AE
cases my receive hospital treatment then are actually present in the
community. For example, in south Ningxi in China, CE
represented 96% of hospital treated cases of echinococcosis, but
ultrasound studies in the local community suggest that 56% of
cases of echinococcosis are AE [36].
The USA and Canada are endemic for E. multilocularis.
However there is very little transmission to man. There have
been reports from Native American communities of high incidence
rates in Alaska [37] but only locally and these have been
eliminated by appropriate intervention programs. Otherwise,
there have only been single cases reports in Minnesota [38] and
Manitoba [39]. Thus there is very little evidence for autochtho-
nous human cases presently in North America despite the active
transmission in animal hosts.
Eastern Europe has highly variable data. The parasite is
endemic in most of the former Soviet States. Lithuania has the best
data and reports incidence rates [40] and it is likely that the other
Baltic States have similar incidences due to similarities in culture,
geography, and population. From central and western Europe
there is usually high quality data giving details of the numbers of
cases (Table 7). The core endemic area is centred on Switzerland,
southern Germany, and eastern France.
In North Africa, there have been two reports of autochthonous
AE from Tunisia and a further case from Morocco diagnosed by
histological examination of the lesions [41,42]. However the
parasite has never been recorded in animals from Africa and in the
absence of molecular confirmation there is insufficient evidence to
confirm any part of North Africa is presently endemic for E.
multilocularis.
AE is a serious disease and, although the prognosis is reasonably
good when treatment is available [3], the prognosis is equally bleak
in the absence of treatment. The overwhelming number of cases
comes from an area of rural China which forms part of the
Tibetan plateau. This population is remote and with few financial
resources with an estimated annual income per head of less than
US$500 [43]. Therefore it is reasonable to assume that most of
these cases will be fatal and hence, the annual mortality due to AE
is similar to the incidence. This is also likely to be true of most
other cases outside of Europe. An annual mortality due to AE of
approximately 18,000 is greater than one tenth of the total
mortality of 177,000 as a result of the 10 diseases of the neglected
tropical disease cluster (trypanosomiasis, Chagas disease, schisto-
somiasis, leishmaniasis, lymphatic filariasis, onchocerciasis, intes-
tinal nematode infections, Japanese encephalitis, dengue, and
leprosy ) [44]. The disease burden can also be compared to that of
rabies. Annual AE mortality is approximately one third of that due
to rabies which has been estimated at approximately 55,000
[45,46]. Nearly all is from Africa and Asia. Unlike rabies, there is
also no vaccine for canid echinococcosis and control requires
repeated treatment of foxes or dogs with praziquantel. Thus,
although AE is rare on a global scale it has a high burden in some
highly endemic communities in China where it is likely to be one
of the leading causes of death.
Likewise the global burden of disease, in terms of DALYs, is
high. This is again due to the very high fatality rate resulting in a
large number of YLLs but additionally due to the expected high
disability weight that individuals have during the course of the
disease. Diseases with similar magnitudes of DALYs include
neglected tropical diseases such as onchocerciasis, and Chagas
disease [47]. An initial estimate of the global burden of cystic
echinococcosis was approximately 1 million DALYs [22].
However, this is likely to be an underestimate [48] and a re-
evaluation of the global burden of CE is ongoing.
Control of this disease depends on the risk factors for
transmission. The wild life cycle can be disturbed through the
treatment of foxes with praziquantel impregnated baits [10].
However, the feasibility of applying such control measures over
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large parts of the Tibetan plateau, where the main burden of AE is
found, would be questionable. Dog contact is a known risk factor
for transmission to man [49] and dogs are highly susceptible to
infection with this parasite [50]. However, it is not known if dogs
participate in the cycle or are aberrant definitive hosts. If they are
aberrant hosts, periodic treatment of dogs will not disturb the
transmission cycle and will have much less effect on long term
transmission rates to humans [43]. Other means of reducing the
disease burden would be through better control of food or water
supplies which may be contaminated with parasite eggs. Such
control would be dependent on the attributable fraction of disease
burden due to these transmission pathways and the cost
effectiveness of such intervention strategies.
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